Forward Industries Inc. (NASDAQ: FWDI)

The QualityStocks Daily Newsletter would like to spotlight Forward Industries Inc. (NASDAQ: FWDI).

Forward Industries (NASDAQ: FWDI) , a Solana treasury company, recently finished its first full reporting period as the world’s largest Solana treasury. A recent article shares details from an announcement of the company’s fiscal first quarter 2026 operating and financial results, updates, milestones and future plans. “As of Dec. 31, 2025, Forward Industries has SOL holdings of over 6.9 million, and almost all of the company’s SOL is staked. (As of the end of 2025, the company has generated over 112,171 SOL in staking rewards.)…Since the company adopted the SOL treasury strategy, FWDI’s validator infrastructure has generated between 6.5% and 7.2% gross annual percentage yield before fees, which outperforms many peer validators.”

To view the full article, visit https://ibn.fm/3O0ue

Forward Industries Inc. (NASDAQ: FWDI) is building and managing a large-scale Solana (SOL) treasury, backed by some of the most influential investors in the digital asset space. The company’s strategy centers on long-term shareholder value through active participation in the Solana ecosystem, which it views as uniquely positioned to underpin future global capital markets due to its high throughput, deep economic activity, and growing developer adoption.

Through this shift, Forward Industries aims to create value by accumulating SOL and strategically deploying assets through on-chain opportunities including staking, lending, and participation in decentralized finance (DeFi). Forward also became the first U.S.-listed company to bring its common stock onto the Solana blockchain, reinforcing its focus on digital-native capital markets.

Forward Industries is headquartered in New York.

Solana Treasury Operations

In September 2025, Forward Industries closed a $1.65 billion private investment in public equity (PIPE) led by Multicoin Capital, Galaxy Digital, and Jump Crypto. The PIPE proceeds were deployed to acquire over 6.8 million SOL at an average price of $232 per token, with a portion executed on-chain via DFlow, a decentralized exchange aggregator built exclusively for Solana trading applications. The company has since staked the entirety of its treasury, actively generating yield through native Solana infrastructure and DeFi applications.

Forward’s strategy is centered on growing SOL per share, leveraging a range of tools including at-the-market (ATM) equity offerings and potential preferred equity issuance. The company is also targeting acquisitions and strategic partnerships within the Solana ecosystem to accelerate treasury yield and ecosystem alignment. As part of its infrastructure expansion, Forward tokenized its FORD shares on the Solana blockchain in collaboration with Superstate and plans to acquire an equity interest in the platform. The tokenized shares are expected to enable 24/7 trading, real-time settlement, and eligibility for use as DeFi collateral.

This shift was supported by the company’s board and executive team, whose composition reflects deep alignment with the Solana ecosystem — including leadership from Multicoin Capital and board observers from Galaxy and Jump Crypto. The company’s stated objective is to establish itself as the leading institutional participant in the Solana ecosystem, uniquely positioned to capture both economic yield and strategic exposure to one of the fastest-growing blockchain networks in the world.

Market Opportunity

Solana has emerged as the most performant blockchain in the digital asset space, processing over 8.9 billion transactions in Q2 2025 and sustaining approximately $3 billion in daily decentralized exchange (DEX) trading volume. Year to date, Solana applications have generated over $4 billion in fees and more than $1 billion in real economic value (REV), a proxy for free cash flow generated by the network.

DeFi participation, stablecoin usage, and developer activity have all grown substantially, with over $1.5 trillion in swap volume recorded through 2025. SOL staking yields have averaged over 8%, comprised of both inflationary rewards and organic yield from network activity. With 17 pending ETF applications and major institutions like BlackRock, Visa, PayPal, and HSBC integrating Solana, Forward Industries is positioned to benefit from a rising tide of institutional adoption, tokenization of real-world assets, and increased demand for high-performance blockchain infrastructure.

Leadership Team

Kyle Samani, Chairman of Forward Industries, is the co-founder and Managing Partner of Multicoin Capital, an early Solana backer and one of the largest holders of SOL. Samani contributed $25 million to the PIPE and is a key strategic leader behind Forward’s treasury roadmap.

Mike Pruitt, Interim CEO of Forward Industries, joined the board in February 2025 and was appointed Interim CEO in May. He is the founder of Avenel Financial Group and previously served as CEO of Chanticleer Holdings, bringing decades of public company leadership and capital markets experience.

Kathleen Weisberg, Chief Financial Officer of Forward Industries, was appointed CFO in July 2023 after serving as Corporate Controller since 2020. Weisberg is a CPA with prior roles at WW International, Symbol Technologies, and Ernst & Young.

Forward Industries Inc. (NASDAQ: FWDI), closed Tuesday's trading session at $4.43, up 2.7842%, on 706,792 volume. The average volume for the last 3 months is 1,005,808 and the stock's 52-week low/high is $4.03/$46.

Recent News

• Forward Industries Inc. (NASDAQ: FWDI) - InvestorNewsBreaks - Forward Industries Inc. (NASDAQ: FWDI) Delivers Strong Results as Solana Treasury Expands
• Forward Industries Inc. (NASDAQ: FWDI) and the Cryptocurrency Market Represent a Rare Opportunity for Investors
• Forward Industries Inc. (NASDAQ: FWDI) Executes the Company's Solana Treasury Strategy to Build on a Successful 2026 Fiscal Q1

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) acknowledged its partner Hastings Technology Metals, alongside Wyloo, for acquiring a fully permitted mixed rare earth chloride production facility in Thailand, a move expected to accelerate near-term processing of monazite feedstock and strengthen a Western-aligned rare earth supply chain. The company said the development supports ongoing discussions toward a long-term supply agreement tied to its Louisiana Strategic Metals Complex, as it works to integrate upstream supply with midstream processing and rare earth oxide production capabilities.

To view the full press release, visit https://ibn.fm/DmB6J

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Tuesday's trading session at $4, up 8.1081%, on 304,261 volume. The average volume for the last 3 months is 325,580 and the stock's 52-week low/high is $0.699/$10.69.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - RockBreaks - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Supports Partner Acquisition of Thailand Rare Earth Processing Facility
• DefenseNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Signs MOU With Vulcan Elements To Develop Rare Earth Magnet Supply Chain
• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Key Federal Milestone for RapidSX Platform

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.S. market of $80 million to $200 million while addressing broader global pain management needs.

To view the full press release, visit https://ibn.fm/QBBSF

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Tuesday's trading session at $3.53, up 2.0231%, on 9,053 volume. The average volume for the last 3 months is 13,837 and the stock's 52-week low/high is $3.42/$11.6779.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Selects Global Brand Name Candidate for AVERSA(TM) Fentanyl Patch
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Secures Costa Rica Approval for Kinesiology Tape Line
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth. The study, whose findings appeared in the journal Nature, shows that androgens don’t play a part in the development of any other kind of brain tumor. The team’s work shows that when the signaling of these hormones is blocked, the growth of the tumors is blocked. This discovery creates a possibility that treatments could be developed to block these hormones to curb the proliferation of these tumors that are currently untreatable. It is notable that in human brains that are growing normally, the cells of this cancer in people with PFA ependymoma tend to be less developed in boys and therefore primed to grow, unlike in females, where the cancer cells are more developed. Their tests showed that when boys with these cells receive androgen supplementation, the cancer cells grow and multiply rapidly. The team concluded that early exposure to androgens promoted this cancer’s growth and administering treatments which inhibit these androgens could slow tumor progression. With more companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) engaged in work geared at developing treatments for primary brain tumors in pediatric and adult patients, we can expect more eye-opening insights about these malignancies to come to light. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $2.39, up 5.2863%, on 5,087 volume. The average volume for the last 3 months is 42,978 and the stock's 52-week low/high is $2.0573/$34.7988.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer
• Misinformation Could Thwart the Potential of Cancer Vaccines
• Fewer Men Undergo Cancer Screening, Study Shows

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline Holdings (NASDAQ: BLNE) reported fourth-quarter 2025 net revenue of $2.5 million, up 127% year over year, on origination volume of $84.7 million, a 44% increase, as the company continued improving loan economics with a 31% rise in average revenue per loan and an 18% reduction in cost per loan. The company also launched its BeelineEquity platform, closing initial blockchain-recorded transactions, while ending the year debt-free and positioning for scalable growth, with management highlighting progress toward cash flow break-even and a long-term goal of reaching a $100 million revenue run rate.

To view the full press release, visit https://ibn.fm/ripDY

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Tuesday's trading session at $2.35, up 11.3744%, on 1,221,848 volume. The average volume for the last 3 months is 651,370 and the stock's 52-week low/high is $0.6202/$4.65.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - MissionIRNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Reports Q4 2025 Revenue Growth of 127% and Expands Blockchain-Based Mortgage Platform
• Beeline Holdings Inc. (NASDAQ: BLNE) Launches Self-Service Mortgage Platform to Offer Greater Flexibility and Control to Borrowers
• Beeline Holdings Inc. (NASDAQ: BLNE) Partners with TYTL Corp on Tokenized Fractional Real Estate Model

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO)

The QualityStocks Daily Newsletter would like to spotlight Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO).

• Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address.
• Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample.
• The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.
• The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs, to expand access to its cardiovascular testing solutions.
• Recent developments include expanded provider partnerships across the United States, finalized CMS reimbursement rates of $854 for its clinical tests, initial international expansion into India, and clinical data presentations supporting its ability to detect forms of coronary heart disease that traditional tools may miss.

Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.

Cardio Diagnostics was founded to develop and commercialize clinical tests and data solutions that enable earlier detection and more precise management of cardiovascular disease across clinical and non-clinical settings.

The company is headquartered in Chicago, Illinois.

Portfolio

The company’s portfolio brings together epigenetic and genetic insights with artificial intelligence to generate actionable information for cardiovascular care. This approach underpins a suite of blood-based tests and platforms designed for use across both individual patient care and broader population health settings.

Epi+Gen CHD™

Epi+Gen CHD™ is a prescription-only blood test that assesses a patient’s three-year risk of a coronary heart disease (CHD) event, including heart attack and sudden death. The test evaluates three epigenetic and five genetic biomarkers and applies artificial intelligence to generate a personalized risk score. It is designed to assess risk regardless of the presence of traditional factors and is non-invasive, requiring no fasting or radiation. In clinical validation studies, the test has demonstrated approximately two times greater sensitivity than conventional risk calculators and enables ongoing monitoring through epigenetic biomarkers that can change in response to intervention.

PrecisionCHD™

PrecisionCHD™ is a prescription-only blood test that aids in the detection and management of coronary heart disease by identifying molecular signals associated with the condition. The test evaluates 10 epigenetic and six genetic biomarkers and uses artificial intelligence to determine whether a disease signal is present. It provides patient-specific insights into the molecular drivers of disease, supporting more individualized care decisions, and is designed to detect both obstructive and non-obstructive forms of CHD in a non-invasive manner.

HeartRisk™

HeartRisk™ is a population-level cardiovascular risk intelligence platform that integrates anonymized clinical, claims, industry, and geographic data to provide real-time insights into heart disease risk across defined populations. The platform enables organizations to quantify risk, project future healthcare costs, benchmark against peer groups, and track changes over time, supporting more informed planning and risk management strategies.

CardioInnovate360™

CardioInnovate360™ is a biopharma research platform that leverages artificial intelligence and epigenetics to support the discovery, development, and validation of cardiovascular therapies. The platform is designed to identify novel biomarkers and disease pathways, optimize clinical trial design through improved patient stratification, and enable the development of scalable, non-invasive diagnostic tools.

Market Opportunity

Cardiovascular disease (CVD) is the leading cause of death in the United States, responsible for nearly one in three deaths. It encompasses a range of conditions, including CHD, stroke, heart failure, and peripheral artery disease, and continues to represent a significant and persistent healthcare burden.

Coronary heart disease is the most common form of CVD and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. In the U.S., one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (INOCA), a subset of CHD.

Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. While an estimated 80–90% of cardiovascular disease is preventable through early detection and proactive management, traditional approaches can leave gaps, as approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%.

Leadership Team

Meesha Dogan, PhD, Chief Executive Officer and Co-Founder, has served as CEO and a director since inception and co-founded the company alongside Dr. Philibert. She has more than a decade of experience working at the intersection of artificial intelligence, epigenetics, and genetics, leading the development and commercialization of DNA-based cardiovascular tests. Dr. Dogan is an inventor on multiple granted and pending patents and holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa.

Robert Philibert, MD, PhD, Chief Medical Officer and Co-Founder, has served as CMO and a director since inception and co-founded the company with Dr. Dogan. He is a professor at the University of Iowa with joint appointments across psychiatry, neuroscience, molecular medicine, and biomedical engineering, and has published more than 200 peer-reviewed manuscripts. Dr. Philibert has received numerous NIH grants and holds patents related to epigenetics, including work on behavioral biomarkers.

Tim Dogan, PhD, Chief Technology Officer, has served as CTO since May 2022 after joining the company in 2019 as its first employee. He played a key role in developing the company’s Integrated Multi-Omics Engine™ and is a co-inventor on multiple patent-pending technologies. Dr. Dogan holds a PhD and BSE/MS degrees in Mechanical Engineering from the University of Iowa.

Elisa Luqman, JD, MBA, Chief Financial Officer, has served as CFO since March 2021 and has experience in public company finance, compliance, and corporate governance. She has held senior leadership roles at Clinigence Holdings Inc. and currently serves as Chief Legal Officer (SEC) at Nutex Health Inc., overseeing SEC reporting and compliance. Ms. Luqman holds a JD and MBA in Finance from Hofstra University.

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), closed Tuesday's trading session at $1.95, up 12.069%, on 76,969 volume. The average volume for the last 3 months is 2,070,617 and the stock's 52-week low/high is $0.97/$17.388.

Recent News

• Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) - Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is 'One to Watch'
• BioMedNewsBreaks - Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Schedules Investor Conference Call for Feb. 19, 2026
• Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The piece reads, “‘We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,’ the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed HeartBeam to transition to commercial-stage status.”

To view the full article, visit https://ibn.fm/NrrYt

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $1.22, up 8.9286%, on 491,773 volume. The average volume for the last 3 months is 2,060,458 and the stock's 52-week low/high is $0.54/$4.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - AINewsBreaks - HeartBeam Inc.'s (NASDAQ: BEAT) 'Significant Turning Point' Spotlighted in Recent Article
• Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

• In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability.
• The significance of the UK designation extends beyond a single program.
• The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease.

A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development that highlights both the potential of the therapy and the growing strength of the company’s rare disease pipeline.

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behçet’s Disease, ongoing development of SGX302 and SGX945 programs and a year-end cash position of approximately $7.9 million, as it continues to pursue strategic options to support late-stage development.

To view the full press release, visit https://ibn.fm/b1p2y

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.18, up 6.3063%, on 202,063 volume. The average volume for the last 3 months is 305,066 and the stock's 52-week low/high is $1/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
• Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Datavault AI Inc. (NASDAQ: DVLT)

The QualityStocks Daily Newsletter would like to spotlight Datavault AI Inc. (NASDAQ: DVLT).

Datavault AI (NASDAQ: DVLT) announced the closing of a definitive agreement with Coppercore Inc. to digitize and tokenize copper resources through its proprietary blockchain platform, targeting the creation of $100 million or more in Coppercoin(TM) digital tokens. Each token will represent five pounds of in-ground copper with pricing linked to COMEX benchmarks, enabling fractional, liquid ownership for global investors, as the company positions the initiative to launch by the end of the second quarter and expand access to the growing copper market tied to AI infrastructure, electrification and energy transition demand.

To view the full press release, visit https://ibn.fm/3Uy1v

Datavault AI Inc. (NASDAQ: DVLT) is a pioneering leader in immersive, wireless sound technology, providing cutting-edge audio solutions for intelligent devices and next-generation home entertainment systems. The company collaborates with top consumer electronics (CE) brands and manufacturers, including industry giants like Harman International (a division of Samsung), LG, Hisense, TCL, Bang & Olufsen, and Platin Audio. WiSA Technologies delivers exceptional wireless sound experiences for high-definition content, including movies, music, sports, gaming, and esports, thereby enhancing the overall consumer experience in home entertainment.

As a founding member of WiSA™ (the Wireless Speaker and Audio Association), WiSA Technologies plays a critical role in defining wireless audio interoperability standards, ensuring seamless integration across devices and platforms. The company actively works with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to promote and market spatial audio technologies, underscoring its commitment to advancing the future of audio and making high-quality, immersive sound accessible to a broader audience.

Headquartered in Beaverton, Oregon, WiSA Technologies extends its global reach with sales teams strategically located in Taiwan, China, Japan, Korea, and California. This international presence allows the company to effectively serve a diverse customer base and maintain strong relationships with key partners worldwide. By continuously innovating and setting new benchmarks in wireless audio, WiSA Technologies is well-positioned to remain at the forefront of the evolving home entertainment landscape.

The WiSA Association

The WiSA® Association, a wholly owned subsidiary of WiSA Technologies, is dedicated to promoting and standardizing spatial audio solutions for home entertainment, ensuring that immersive audio experiences are accessible to everyone. In collaboration with leading consumer electronics companies, technology providers, retailers, and ecosystem partners, the association works to advance wireless audio technology across various devices, making high-quality sound an integral part of modern home entertainment systems. As a key player in the industry, WiSA LLC, also known as the Wireless Speaker and Audio Association, is instrumental in fostering the adoption and integration of cutting-edge audio technologies.

Recently, the WiSA Association significantly expanded its influence by executing licensing agreements with leading HDTV brands, covering 43% of the HDTV market that uses the Android operating system, the most widely used OS in the market. By focusing on Android-based HDTVs and collaborating with speaker manufacturers, WiSA is actively building an ecosystem of WiSA E-enabled speaker systems, mirroring the success of its earlier WiSA HT technology. This strategic initiative, combined with WiSA E’s compatibility with multiple HDTV SoC providers and support for spatial audio formats like Dolby Atmos FlexConnect, positions the association at the forefront of transforming home audio experiences, driving widespread adoption across the home entertainment landscape.

Market Opportunity

From an investment perspective, WiSA Technologies Inc. is strategically positioned to capitalize on the growing demand for wireless and immersive audio experiences as consumer preferences shift toward high-definition home entertainment systems. As streaming services, gaming, and smart home technologies continue to expand, the need for seamless, high-quality audio solutions is becoming increasingly critical. WiSA Technologies, with its innovative wireless sound technology and strong partnerships with leading consumer electronics brands, is well-placed to capture a significant share of this expanding market, particularly as more consumers seek to enhance their home entertainment experiences.

Moreover, the company’s focus on setting industry standards through the WiSA Association further solidifies its role as a key player in the evolving audio landscape. By driving the adoption of wireless audio interoperability standards, WiSA Technologies not only ensures broad compatibility across devices but also positions itself as a leader in the market, capable of influencing future trends and technologies. This proactive approach, combined with its established global presence and collaborations with top-tier brands, provides WiSA Technologies with a strong foundation for sustained growth, making it an attractive opportunity for investors looking to gain exposure to the burgeoning home entertainment and smart audio sectors.

Leadership Team

Brett Moyer is the Chief Executive Officer, President, and Chairman of WiSA Technologies, Inc., and a founding member of the company. He has served in these leadership roles since August 2010. Prior to this, Mr. Moyer was the president and CEO of Focus Enhancements, Inc., where he oversaw the development and marketing of proprietary video technology. He has a rich background in consumer electronics, having held key positions at Zenith Electronics Inc., including Vice President and General Manager of its Commercial Products Division. Mr. Moyer also serves on the board of directors of Alliant International University and has previously served on the boards of HotChalk, Inc., and NeoMagic Corporation. He holds a Bachelor of Arts in Economics from Beloit College and an MBA in Finance and Accounting from Thunderbird School of Global Management.

Gary Williams is the Chief Accounting Officer and Vice President of Finance at WiSA Technologies, Inc., roles he has held since September 2019 and the company’s founding in August 2010, respectively. He previously served as the company’s Chief Financial Officer and Secretary until 2019. Mr. Williams has extensive experience in finance, having served as CFO of Quantum3D, Inc., and in similar roles at Focus Enhancements Inc. and Videonics Inc. He began his career in public accounting with Coopers & Lybrand LLP. Mr. Williams is a certified public accountant (inactive) and holds a bachelor’s degree in business administration with an emphasis in accounting from San Diego State University.

Datavault AI Inc. (NASDAQ: DVLT), closed Tuesday's trading session at $0.6183, up 11.4054%, on 31,685,309 volume. The average volume for the last 3 months is 43,450,873 and the stock's 52-week low/high is $0.2512/$4.1.

Recent News

• Datavault AI Inc. (NASDAQ: DVLT) - TechMediaBreaks - Datavault AI Inc. (NASDAQ: DVLT) Launches $100 Million Copper Tokenization Initiative With Coppercore
• AINewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Issues Corrected Release On Mandela Dollar Stablecoin Initiative
• Web3MediaBreaks - Datavault AI Inc. (NASDAQ: DVLT) Partners With American Strategic Minerals On $78.2 Million Tokenization Initiative

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)

Disseminated on behalf of Canamera Energy Metals Corp., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF).

This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) provided an update on exploration across its seven-project portfolio spanning Brazil, the United States and Canada, highlighting ongoing REE drilling at its Turvolândia and Patos projects in Brazil, geophysical modelling at the Iron Hills project in Colorado and advancing technical and permitting work across three Ontario assets. The company also reported raising approximately $10.2 million over the past four months, positioning it to execute near-term exploration programs and support continued portfolio expansion, with multiple assay results, surveys and technical milestones expected over the coming months.

To view the full press release, visit https://ibn.fm/Gmx4d

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) is a rare earth and critical metals exploration company focused on developing a diversified portfolio of district-scale opportunities across the Americas. The company targets jurisdictions with supportive regulatory frameworks, strong geological signatures, and increasing strategic relevance as global supply chains seek alternatives to China’s rare earth dominance. Its assets span ionic clay systems in Brazil, carbonatite complexes in the United States and Canada, and underexplored terrains with meaningful geophysical and geochemical indicators.

Guided by a vision to support North American and allied rare earth supply chains, Canamera concentrates on high-conviction targets where early entry, scalable land positions, and efficient exploration can potentially unlock long-term value. The company’s mission is centered on generating discoveries aligned with the accelerating global demand for critical minerals essential to defense, advanced manufacturing, clean energy technology, and next-generation electronics. Through systematic data-driven exploration, Canamera aims to advance projects aligned with growing efforts to diversify rare earth supply across strategic jurisdictions.

The company is headquartered in Edmonton, Alberta.

Projects

Turvolândia – Minas Gerais, Brazil

Canamera holds an option to acquire up to a 100% ownership interest in the Turvolândia Rare Earth Ionic Clay Project, a 29,574-hectare land package located in Minas Gerais, Brazil’s top mining state and a region responsible for over 30% of national mineral output. The project sits within a prolific corridor of REE-rich alkaline rocks associated with the Poços de Caldas Complex, currently being advanced by multiple industry developers.

Turvolândia benefits from year-round road access, established infrastructure, and supportive local communities. The geological setting includes the São Vicente and Pouso Alegre complexes, where heavily weathered horizons host REE-enriched clays and minerals such as monazite and bastnäsite.

Early exploration confirms REE-bearing clays, with upcoming work focused on property-wide soil sampling and deeper drilling to test the primary ionic clay enrichment horizon and depth potential.

São Sepé – Rio Grande do Sul, Brazil

Canamera also holds an option to acquire up to a 100% interest in the São Sepé Project, which comprises 7,966 hectares in a province known for significant mining activity, including coal, gems, and titanium, and offers strong infrastructure and accessibility. The geology is dominated by an 11-km Rapakivi granite body and advanced-weathered granitoid rocks prospective for potential ionic clay REE mineralization.

While currently undrilled, initial soil sampling indicates the presence of REE enrichment potential. Three priority targets—Erica, Sara, and Maya—have been identified, with planned work including systematic soil sampling and drilling across defined zones. The project also covers a notable uranium-potassium-thorium anomaly, further supporting its rare earth potential.

Iron Hills – Colorado, USA

The Iron Hills Project consists of 85 unpatented lode claims totaling 1,756 acres, held at 100% ownership and located within the Iron Hills / Powderhorn carbonatite complex, one of the premier carbonatite-alkaline systems in the United States. Adjacent to Teck Resources’ Iron Hill deposit, host to one of the country’s largest rare earth oxide and titanium deposits, the project spans two non-contiguous claim blocks positioned along mapped intrusive contacts, felsite porphyry boundaries, and carbonatite dike projections.

Canamera staked these claims in 2025 as part of its U.S. expansion strategy supported by Rangefront Mining Services, and they are pending approval by the BLM.

Schryburt Lake – Ontario, Canada

Through a Joint Venture Option Agreement, Canamera may earn up to a 90% interest in the Schryburt Lake Project, a multi-center carbonatite-hosted REE–Nb system defined by four priority targets: Blue Jay, Goldfinch, Blackbird, and Starling.

These prospects exhibit coincident thorium radiometric highs, coherent magnetic bodies, surface anomalies, and historical trenching. Together, they outline the potential for a vertically extensive and multi-center REE–Nb system. Planned work includes a ~1,000-meter heli-supported scout drilling program following permitting and community consultation.

Garrow – Ontario, Canada

The Garrow Project covers 2,182 hectares located 43 km north-northeast of North Bay and is accessible year-round with strong local infrastructure. Canamera holds an option to acquire a 100% interest in the property.

Regional geochemical datasets include 26 samples above 500 ppm REE across Ontario, and three of these high-value anomalies occur within the Garrow Township area, making it a compelling target for early-stage exploration, including property-wide soil sampling and geophysics to delineate initial drill targets.

Market Opportunity

Rare earth elements play a central role in high-growth industries including electric vehicles, wind turbines, robotics, high-performance electronics, defense systems, and medical imaging, underpinning global trends in electrification, automation, and advanced manufacturing. Their application in permanent magnets, optics and lasers, catalysts, and nuclear and medical technologies positions them as foundational materials for both industrial innovation and national security.

Global demand for rare earth elements is projected to triple—from 59,000 tonnes in 2022 to 176,000 tonnes by 2035—driven by rapid EV adoption and wind-power expansion, with supply expected to lag by up to 30%, according to McKinsey & Company. The global REE market, valued at $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030 at a compound annual growth rate of approximately 8.6%, according to Grand View Research, reflecting a sustained and widening supply-demand imbalance that supports new project development.

China currently controls approximately 60% of global rare earth mining and about 90% of processing capacity, reinforcing persistent price volatility and supply-chain concentration that have been highlighted by historical export restrictions, environmental crackdowns, and geopolitical disruptions. In response, North American governments have accelerated initiatives to strengthen domestic critical-minerals supply chains, including $1 billion in U.S. Department of Energy funding opportunities and Canada’s C$1.5 billion Critical Minerals Infrastructure Fund. Together, these structural shortages, policy tailwinds, and long-term electrification trends underscore the strategic relevance of Canamera’s diversified rare earth portfolio across Brazil, the United States, and Canada.

Leadership Team

Brad Brodeur, CEO & Director, brings more than 27 years of capital markets experience focused on venture-stage issuers, having led over $100 million in financings for junior and start-up companies following senior advisory roles at Raymond James, Canaccord Genuity, and Edward Jones.

Warren Robb, VP Exploration, brings over 35 years of global mineral exploration experience across North America, China, Africa, and South America, including senior roles with Nexus Gold, WPC Resources (now Bluestar Gold), Roxgold, TTM Resources, Majestic Gold, and Trivalence Mining.

Jelena Veljovic, CFO, brings public-company financial reporting and accounting expertise through her work with Treewalk Consulting in Vancouver, supported by prior experience in taxation and private-company accounting at Focus LLP in Calgary.

All technical and scientific information disclosed herein was reviewed and approved by Warren Robb, P.Geo (British Columbia), Vice-President, Exploration, of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For a discussion of the Company’s QA/QC and data verification processes and procedures, please see its most recently filed technical report, a copy of which is available under Canamera’s profile at www.sedarplus.ca.

Canamera Energy Metals Corp. (OTCQB: EMETF), closed Tuesday's trading session at $0.2356, up 2.4348%, on 84,585 volume. The average volume for the last 3 months is 153,020 and the stock's 52-week low/high is $0.2/$0.94.

Recent News

• Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) - MiningNewsBreaks - Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) Advances Multi-Project Exploration Portfolio Following $10.2 Million Financing
• Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) Expands Ionic Clay Rare Earth Footprint in Brazil
• Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) Provides Update on the Turvolândia Rare Earth Project as they Target Rare Earth Elements

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF)

The QualityStocks Daily Newsletter would like to spotlight Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF).

This article has been disseminated on behalf of Fairchild Gold Corp. and may include paid advertising.

Fairchild Gold (TSX.V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) announced it will adopt a semi-annual financial reporting framework under Coordinated Blanket Order 51-933, allowing the company to forgo first- and third-quarter filings while continuing to report audited annual results and mid-year financials. The company said it qualifies for the program as a TSX Venture Exchange-listed issuer with less than $10 million in annual revenue and a clean 12-month disclosure record, with updated reporting timelines beginning in fiscal 2026.

To view the press release, visit https://ibn.fm/lmzoO

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions across North America. The company targets projects with historical production, strong multi-metal potential, and clear pathways to discovery through modern geoscience, AI integration, and responsible development practices.

Fairchild’s portfolio is anchored by the Nevada Titan Project, a district-scale, copper-gold system located just outside Las Vegas in the prolific Walker Lane Belt. The company has also entered into an MOU to acquire the advanced-stage Golden Arrow Project in Nevada, subject to completion of a definitive agreement, and it holds 100% ownership of the Fairchild Lake Property in Ontario.

Fairchild’s mission is to build long-term value by identifying overlooked mineralized systems and unlocking their potential using modern exploration methods.

The company is headquartered in Vancouver, British Columbia.

Projects

Nevada Titan Project (Goodsprings District, Nevada)

Nevada Titan is Fairchild’s flagship asset and a district-scale, multi-metal opportunity located just 55 kilometers southwest of Las Vegas. Spanning over 6,150 acres (300+ claims), the project sits within the historically productive Goodsprings Mining District—part of the prolific Walker Lane Belt and Battle Mountain Trend extension. The area hosts numerous historic mines, including Copperside, Copper Chief, Azurite, and Fitzhugh Lee, yet remains largely untested by modern drilling.

Surface sampling and geological mapping have confirmed high-grade copper mineralization up to 34.0% Cu, with associated values of gold, silver, molybdenum, and platinum group elements. A 1.5-kilometer copper-gold corridor has been identified, showing pods and lenses of mineralization consistent with a porphyry-skarn-CRD system. Notably, the discovery of a hydrothermal breccia pipe with garnet-bearing skarn textures and elevated molybdenum signals a porphyry-affiliated source at depth.

Ongoing exploration includes drone magnetics, AI-integrated targeting, and induced polarization geophysics. With infrastructure already in place and proximity to Las Vegas contractors, Fairchild is preparing for a 2026 drill campaign focused on unlocking the project’s large-scale copper-gold system.

Golden Arrow Project (Walker Lane Shear Zone, Nevada)

In September 2025, Fairchild signed a Memorandum of Understanding to acquire 100% of the Golden Arrow Project, an advanced-stage gold-silver asset in Nevada’s Walker Lane Trend. The project hosts a historic mineral resource estimate of approximately 347,000 ounces of gold and 5.3 million ounces of silver, including 296,500 ounces of gold and 4.0 million ounces of silver in the measured and indicated categories. According to third-party analysis by mining analyst Ryan D. Long, the total acquisition consideration of $5.0 million equates to approximately $12 per ounce of gold in the ground.

The project’s two main deposits, Gold Coin and Hidden Hill, were historically mined at surface and remain open at depth, supported by over 61,000 meters of past drilling. Modern geophysical work has outlined 34 additional exploration targets, including six classified as high-priority. Hosted in a volcanic complex with both high-grade vein and disseminated mineralization, the system offers strong potential for expansion.

Golden Arrow is situated just 96 kilometers from Kinross’s 28-million-ounce Round Mountain Mine and expands Fairchild’s Nevada footprint by 170% when combined with the Titan Project. The project’s extensive exploration database and near-surface deposits make the acquisition a compelling strategic entry point into a proven district with significant near-term development potential.

Fairchild Lake Property (Savant Lake Greenstone Belt, Ontario)

Fairchild Gold holds 100% ownership of the Fairchild Lake Property, a 2,224-hectare claim package in Ontario’s underexplored Savant Lake greenstone belt. Historical and recent work, including airborne geophysics and soil sampling, has identified anomalous gold values near the Kashaweogama Lake Fault, a major crustal break. The company draws geological comparisons to Red Lake’s LP Fault and views the structural setting as a promising focus for future exploration.

Market Opportunity

Fairchild operates in Tier-1 mining jurisdictions where political stability, established infrastructure, and clear permitting pathways reduce development risk and enhance long-term value. Nevada, in particular, is a top-ranked global destination for mineral exploration and home to some of the world’s most productive gold and copper belts. Fairchild’s flagship project, Nevada Titan, is located in the Walker Lane Belt, a prolific trend responsible for more than 89 million ounces of gold and nearly 1 billion ounces of silver to date.

The company is strongly positioned to benefit from the ongoing historic bull market in gold. In early October 2025, Goldman Sachs raised its December 2026 gold price forecast to $4,900 per ounce, citing strong ETF inflows and sustained central bank demand. A Jefferies analyst has projected gold could reach $6,600 per ounce in the near term, while other major institutions including UBS and Bank of America have also raised their targets amid elevated geopolitical risk, structural reserve diversification, and anticipated U.S. rate cuts. With limited new supply and rising demand from both institutional and retail investors, gold remains a cornerstone of portfolio hedging and upside exposure.

Copper also remains a core strategic focus, with demand expected to double by 2035, driven by electrification, grid modernization, and clean energy buildout, according to S&P Global. The Nevada Titan Project hosts porphyry-style copper-gold mineralization, along with skarn and carbonate replacement features—deposit types that are key global sources of both industrial and precious metals.

Leadership Team

Nikolas Perrault, CFA, Executive Chairman, brings over 35 years of experience in capital markets, securities trading, and strategic advisory roles. He began his career with Canada’s top financial institutions and has since focused on guiding small to mid-cap companies through public listings, M&A, and capital raising. He holds a Chartered Financial Analyst designation and a Bachelor of Commerce.

Luís Martins, President and CEO, brings over 40 years of experience in the exploration and mining sector. He previously served as Director of the Mineral Resources Department at Portugal’s Geological Survey and as Director of Mines and Quarries at the Directorate-General of Energy and Geology. He has coordinated international working groups focused on raw materials and mineral policy and has authored more than 100 scientific publications.

Dr. Sergei Diakov, Chair of the Technical Committee and Senior Advisor, is a globally recognized geologist and former discovery lead at both BHP and AngloGold Ashanti. His track record includes major copper-gold discoveries such as Oyu Tolgoi in Mongolia and Nuevo Chaquiro in Colombia. Dr. Diakov brings decades of senior experience managing exploration teams, overseeing risk across geologic and ESG domains, and executing discovery-driven development strategies.

Adam Cavise, Independent Director, brings over 25 years of capital markets experience and has been directly involved in structuring and closing more than $100 billion in public and private equity offerings, SPACs, and recapitalization transactions. Currently a partner at Revere Securities in New York, he has held senior equity roles at Kingswood, Spartan Capital, and Macquarie, and is well regarded for his deep Wall Street network and leadership in equity capital markets.

Fairchild Gold benefits from a deeply experienced leadership and advisory team with expertise across exploration, capital markets, and corporate development. To view the full team, click here.

Fairchild Gold Corp. (OTC: FCHDF), closed Tuesday's trading session at $0.07353, up 8.8688%, on 245,900 volume. The average volume for the last 3 months is 107,380 and the stock's 52-week low/high is $0.0306/$1.

Recent News

• Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) - InvestorNewsBreaks - Fairchild Gold (TSX.V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) Transitions To Semi-Annual Financial Reporting Under TSXV Pilot Program
• MiningNewsBreaks - Fairchild Gold (TSX-V: FAIR) (OTCQB: FCHDF) (Frankfurt: Y4Y) Expands Nevada Titan Property and Initiates CSAMT Survey
• RockBreaks - Fairchild Gold (TSX-V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) Receives Updated NI 43-101 Technical Report for Golden Arrow Project

Frontieras North America Inc.

The QualityStocks Daily Newsletter would like to spotlight Frontieras North America Inc.

Frontieras North America took center stage in the latest GotStocks Podcast episode released by IBN, featuring Co-Founder and CEO Matthew McKean discussing the company’s patented FASForm(TM) technology and its ability to convert coal and other solid hydrocarbons into higher-value outputs such as jet fuel, diesel and technical carbon. The interview also outlines Frontieras’ commercialization strategy, including development of a large-scale facility in West Virginia, its global patent footprint and plans for expansion across North America and international markets.

To view the full press release, visit https://ibn.fm/vLbcZ

Frontieras North America will host a groundbreaking ceremony on Thursday, April 2, 2026, at 11:30 a.m. ET for its first commercial FASForm(TM) facility in Mason County, West Virginia, with a livestream broadcast from Point Pleasant allowing remote audiences to participate in the milestone event. The ceremony will feature remarks from company leadership and government officials and mark the launch of an estimated $850 million project expected to create approximately 300 full-time jobs and 2,000 construction roles as the company advances commercialization of its solid carbon fractionation technology.

To view the livestream, visit https://ibn.fm/1CtAM

Frontieras North America Inc. is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm™, a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon™, a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm™ facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon™, sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm™ facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm™ facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Josephe Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm™ process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

Recent News

• Frontieras North America Inc. - InvestorNewsBreaks – Frontieras North America to Livestream April 2 Groundbreaking for First Commercial FASForm(TM) Plant
• InvestorNewsBreaks – Frontieras North America Featured in IBN GotStocks Podcast Highlighting FASForm(TM) Technology
• InvestorNewsBreaks – Frontieras North America Appoints Three Industry Veterans to Board of Directors